Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab with Chemoradiotherapy for GEJ/Cardia Cancer
NCT02730546Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2016
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in gastroesophageal junction adenocarcinoma and Gastric cardia adenocarcinoma (GCA), sponsored by Mayo Clinic. Primary endpoints: Pathological Complete Response Rate up to 3 years and Safety and Tolerability up to 3 years. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinomaGastric cardia adenocarcinoma (GCA)
Beyond the preview
Go deeper on NCT02730546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02730546.